Last reviewed · How we verify

M. Medici — Portfolio Competitive Intelligence Brief

M. Medici pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
LT3 (liothyronine) LT3 (liothyronine) phase 3 Thyroid hormone replacement Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ) Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Al-Kindy College of Medicine · 1 shared drug class
  2. Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
  3. IBSA Institut Biochimique SA · 1 shared drug class
  4. Merck Sharp & Dohme LLC · 1 shared drug class
  5. Meyer Children's Hospital IRCCS · 1 shared drug class
  6. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 shared drug class
  7. Oregon Health and Science University · 1 shared drug class
  8. Pfizer Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for M. Medici:

Cite this brief

Drug Landscape (2026). M. Medici — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/m-medici. Accessed 2026-05-17.

Related